3.45
0.15%
0.01
前日終値:
$3.44
開ける:
$3.44
24時間の取引高:
82,043
Relative Volume:
0.08
時価総額:
$649.41M
収益:
$12.99M
当期純損益:
$-74.39M
株価収益率:
-7.50
EPS:
-0.46
ネットキャッシュフロー:
$-78.92M
1週間 パフォーマンス:
-5.10%
1か月 パフォーマンス:
-15.36%
6か月 パフォーマンス:
+7.32%
1年 パフォーマンス:
+88.25%
Arbutus Biopharma Corp Stock (ABUS) Company Profile
名前
Arbutus Biopharma Corp
セクター
電話
604-419-3200
住所
701 VETERANS CIRCLE, WARMINSTER, PA
ABUS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
ABUS | 3.445 | 649.41M | 12.99M | -74.39M | -78.92M | -0.46 |
VRTX | 445.81 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 735.95 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 584.00 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 247.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.25 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2022-02-02 | アップグレード | Jefferies | Hold → Buy |
2021-02-25 | 開始されました | Jefferies | Hold |
2020-12-17 | 開始されました | H.C. Wainwright | Buy |
2020-07-27 | 再開されました | JMP Securities | Mkt Outperform |
2020-07-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2020-05-19 | アップグレード | Wedbush | Neutral → Outperform |
2020-03-06 | アップグレード | Chardan Capital Markets | Neutral → Buy |
2020-02-20 | 開始されました | Robert W. Baird | Outperform |
2020-02-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
2019-10-07 | 繰り返されました | B. Riley FBR | Buy |
2019-10-04 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
2018-10-16 | アップグレード | B. Riley FBR | Neutral → Buy |
2018-10-15 | アップグレード | Wedbush | Underperform → Neutral |
2018-10-12 | 繰り返されました | Chardan Capital Markets | Buy |
2018-07-06 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
2018-03-19 | 再開されました | Chardan Capital Markets | Buy |
2018-03-19 | ダウングレード | Wedbush | Outperform → Neutral |
2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
2017-04-04 | アップグレード | Chardan Capital Markets | Neutral → Buy |
2017-02-01 | 繰り返されました | Wedbush | Outperform |
2016-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
2016-11-30 | アップグレード | Chardan Capital Markets | Neutral → Buy |
すべてを表示
Arbutus Biopharma Corp (ABUS) 最新ニュース
Arbutus Biopharma (NASDAQ:ABUS) Earns "Buy" Rating from Chardan Capital - MarketBeat
HC Wainwright Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B Treatment - MyChesCo
Arbutus Biopharma Announces Positive Data from Clinical Trials at AASLD – The Liver Meeting® 2024 - Defense World
Promising New Data from Hepatitis B Trial by Arbutus and Barinthus - MyChesCo
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 16.0% in October - Defense World
ArriVent BioPharma Reports Advancements and Q3 2024 Financial Results - MyChesCo
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Update - MarketBeat
Two Seas Capital LP Adjusts Stake in Arbutus Biopharma Corp - GuruFocus.com
Arbutus to Present at Jefferies London Healthcare Conference - Yahoo Finance
Creative Planning Raises Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
HC Wainwright Has Negative Forecast for ABUS FY2024 Earnings - MarketBeat
HC Wainwright Expects Weaker Earnings for Arbutus Biopharma - Defense World
HC Wainwright Reaffirms “Buy” Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World
Arbutus Biopharma 8-K Filing: Financial Results and Corporate Presentation Update - Defense World
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Earnings Call Transcript - Insider Monkey
JMP Securities Increases Arbutus Biopharma (NASDAQ:ABUS) Price Target to $5.00 - Defense World
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
HC Wainwright Reaffirms Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ... By GuruFocus - Investing.com Canada
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance
Arbutus Fades on Q4 Results - Baystreet.ca
Arbutus Biopharma earnings missed, revenue fell short of estimates - Investing.com
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arbutus Biopharma Corp Q3 2024 Earnings: EPS Loss of $0.10 Meets Estimates, Revenue Falls Short at $1.3 Million - GuruFocus.com
Arbutus: Q3 Earnings Snapshot - San Francisco Chronicle
Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Arbutus Biopharma (ABUS) Set to Announce Earnings on Wednesday - MarketBeat
Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update - Yahoo Finance
SG Americas Securities LLC Acquires New Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Target of Unusually High Options Trading (NASDAQ:ABUS) - MarketBeat
Arbutus Biopharma Corp (ABUS) Stock: A Year of Declines and Increases - The InvestChronicle
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 5.7%Still a Buy? - MarketBeat
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLDThe Liver Meeting® 2024 - Yahoo Finance
Arbutus Biopharma announces officer retirement terms By Investing.com - Investing.com South Africa
Arbutus Biopharma announces officer retirement terms - Investing.com India
Arbutus Biopharma CSO Michael Sofia Announces Retirement Plans - TipRanks
Examining Arbutus Biopharma Corp (ABUS) stock is warranted - US Post News
Arbutus Biopharma Corp [ABUS] stock for 32,637 USD was sold by MANCHESTER KEITH S - Knox Daily
Balance Sheet Dive: Arbutus Biopharma Corp (ABUS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Top investors say Arbutus Biopharma Corp (ABUS) ticks everything they need - SETE News
XTX Topco Ltd Buys Shares of 17,038 Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Jefferies Upgrades Arbutus Biopharma Corp (ABUS) to a Buy from a Hold - Knox Daily
How to interpret Arbutus Biopharma Corp (ABUS)’s stock chart patterns - US Post News
Taking on analysts’ expectations and winning: Arbutus Biopharma Corp (ABUS) - SETE News
Arbutus Biopharma Corp (ABUS)’s Day in Review: Closing at 3.85, Up by 0.52 - The Dwinnex
Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference - Yahoo Finance
Arbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Up 8.3% in September - MarketBeat
Wall Street SWOT: Arbutus Biopharma stock navigates legal wins and pipeline focus - Investing.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 2.8% - MarketBeat
Arbutus Biopharma Corp (ABUS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):